Boston Therapeutics, an innovator of drugs that target
diabetes using complex carbohydrate chemistry, today announced the appointment
of three management positions within its ranks. Effective immediately, Edward
Shea will serve as Vice President Business Development, Tina M. Gagnon will
serve as Consulting Director of Finance, and Yael T. Bobruff, Ph.D. will serve
as Clinical Affairs Manager, respectively.
David Platt, Ph.D., Chief Executive Officer, Boston
Therapeutics, said, “As Boston Therapeutics enters the next phase of its
growth, it is imperative that we attract top talent to help us advance and
commercialize our drug development programs. Ed Shea and Tina Gagnon’s business
and finance backgrounds, and Dr. Bobruff’s expertise in biology and research significantly
strengthen our management team. I am pleased they have decided to join our
company, and I look forward to working with them in the months and years
ahead.”
Mr. Shea boasts of 25 years of experience in commercial
development, marketing, and sales. Of that, 15 years of his experience includes
business development, marketing, and sales leadership positions with
GlaxoSmithKline and Salix Pharmaceuticals, as well as business development
capacities with two startup biopharmaceutical companies, ViroPharma and
Critical Therapeutics. Mr. Shea most recently worked with ViroPharma, Inc. as
Sr. Eastern Area Sales Director. He holds a B.S. in Business/Marketing and an
M.B.A. from Salve Regina University in Newport, RI.
Ms. Gagnon brings over 20 years of experience in finance.
Most recently, she worked as Corporate Controller at Micronetics, Inc., at
which she oversaw a staff responsible for accounts receivable, accounts
payable, inventory management, and other activities. Beforehand, she served in
the following capacities: Controller at Amherst Technologies, LLC; Assistant
Controller of Fruit of the Loom’s Sports & Licensing Division; and Senior
Corporate Auditor at Standex International Corp. Ms. Gagnon holds a B.S. in
Accountancy from Bentley College.
Most recently, Dr. Bobruff was a postdoctoral researcher in
the Department of Systems Biology at Harvard University Medical School in
Boston. There, she investigated in depth the genetic processes and mechanisms
contributing to the evolution of host-pathogen interactions. Dr. Bobruff holds
a B.Sc. in Biology from the Hebrew University of Jerusalem, a M.Sc. in Civil
and Environmental Engineering, and a Ph.D. in Biological Science from Stanford
University.
For more information, visit www.bostonti.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment